Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (Nasdaq: CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company whose news flow is driven by developments in its allogeneic CAR-T cell therapy programs and related corporate updates. The company focuses on vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma.
News about Caribou frequently covers clinical trial milestones, including data readouts from the ANTLER phase 1 trial of vispa-cel and the CaMMouflage phase 1 trial of CB-011. Company press releases have highlighted efficacy and durability data in defined patient cohorts, safety profiles that support outpatient administration for vispa-cel, and dose selection and expansion plans for CB-011 in heavily pretreated multiple myeloma populations.
Investors and followers of CRBU can also expect updates on regulatory interactions and designations, such as RMAT, Fast Track, and Orphan Drug status, as well as communications about planned pivotal trial designs. In addition, Caribou issues quarterly financial results and business updates via press releases and Form 8-K filings, which provide context on its operating runway, research and development spending, and strategic pipeline prioritization.
Another recurring category of news involves conference participation and webcasts, where Caribou’s management and clinical investigators present data at major hematology and oncology meetings and biopharma investor conferences. These events often coincide with new clinical data disclosures or discussions of next steps in trial development.
This news page aggregates such announcements so readers can follow Caribou’s progress in CRISPR-based genome editing, allogeneic CAR-T development, and its lead programs in lymphoma and multiple myeloma. For those tracking CRBU, regular review of this feed helps monitor key clinical, regulatory, and corporate milestones.
Summary not available.
Summary not available.
Summary not available.
Caribou Biosciences (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in upcoming investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, is scheduled to present at two events in June:
1. Jefferies Healthcare Conference in New York, NY on June 7, 2023, at 3:00 pm EDT
2. Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on June 13, 2023, at 3:20 pm PDT
Both presentations will be available via webcast. Interested parties can access the webcasts through the Events page on Caribou's website. The recordings will remain accessible for 30 days after each event.
Caribou Biosciences (Nasdaq: CRBU) reported Q1 2023 financial results and provided a business update. Key highlights include:
1. CB-010: Dose expansion in ANTLER Phase 1 trial for second-line LBCL patients; dose escalation data expected in H2 2023.
2. CB-011: CaMMouflage Phase 1 trial enrolling r/r MM patients; received Fast Track designation.
3. CB-012: IND application for r/r AML planned for H2 2023.
4. Financial position: $291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023; runway into 2025.
5. Q1 2023 results: Revenue $3.5 million, R&D expenses $25.7 million, G&A expenses $8.9 million, net loss $28.0 million.
Summary not available.
Summary not available.
Caribou Biosciences (Nasdaq: CRBU) announced promising preclinical results for CB-012, a CRISPR-edited CAR-T cell therapy targeting relapsed or refractory acute myeloid leukemia (r/r AML), during the 2023 AACR Annual Meeting. The study indicated CB-012 shows enhanced antitumor activity, prolonged survival in AML xenograft models, and protective immune cloaking against NK cell-mediated cytotoxicity. The therapy is engineered with advanced Cas12a chRDNA technology, enabling five genomic edits for improved efficacy. Caribou plans to submit an IND application for CB-012 in H2 2023, signaling a key step in its clinical development strategy. CEO Rachel Haurwitz stated the data supports advancing CB-012 for clinical trials.
Caribou Biosciences (Nasdaq: CRBU) announced that the FDA has granted Fast Track designation to its investigational therapy, CB-011, for treating relapsed or refractory multiple myeloma (r/r MM). This designation facilitates communication with the FDA during the clinical review process. The CaMMouflage Phase 1 trial, which has recently commenced patient dosing, aims to develop CB-011 as an accessible off-the-shelf treatment option, eliminating the need for lengthy manufacturing and complex procedures. CB-011, derived from Caribou's CAR-T platform, employs advanced genome-editing techniques to enhance antitumor capabilities. The company continues to focus on developing cutting-edge therapies for serious diseases.
Caribou Biosciences (Nasdaq: CRBU) announced the first patient has been dosed in the CaMMouflage Phase 1 trial of CB-011, an allogeneic anti-BCMA CAR-T cell therapy aimed at patients with relapsed or refractory multiple myeloma. This trial seeks to evaluate the safety and efficacy of the therapy, utilizing an innovative immune cloaking strategy to enhance antitumor activity by mitigating rejection from T and natural killer cells. As part of Caribou's aim to address unmet needs in treatment accessibility, the trial will include adults with extensive prior therapies. The company plans to continue patient enrollment to assess CB-011's therapeutic potential.